AVIR Atea Pharmaceuticals, Inc.

XNAS 3.93 +0.00% After hours
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

AVIR $3.93 ▲ +0.00%
Key stats
$3.93
After hours $3.93 +0.00%
52-Week Range
$2.92 – $6.45
YTD
+12.93%
IV Rank (30D)
66.15
Straddle Price
$0.88
P/C Vol Ratio
0.44
Market Cap
$0.3B
Open
$3.96
Day Range
$3.91 – $4.05
Volume
291,342
Prev Close
$3.99
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.12%
Beta vs SPY0.96
Cost of Equity (CAPM)9.91% (VRP-adj)
WACC9.78%
Volatility Risk Premium+89.5pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-88.5%
Book / Price54.9% — banking bias active (P/B is primary)
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$4.70 (Market Anchor value)
SMA 20 / Bollinger Mid$4.19
Bollinger Width / SMA2012.2% (drives anchor stability)
Net Debt$-0.1B
Market Cap$0B
Peers used for multiples: BIIB, REGN, UTHR (filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
89%
20-Day Fair Value
≈ by Dec 18, 2026
$3.95
α +0.4% rank 68%
conviction
42%
40-Day Fair Value
≈ by Jan 18, 2027
$3.98
α +1.4% rank 66%
conviction
77%
60-Day Fair Value
≈ by Feb 16, 2027
$4.06
α +3.3% rank 64%
conviction
89%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 20.6× · 3 peers
Peer EV/EBITDA n/a 0% median 18.3× · 3 peers
Peer P/B $6.48 18% median 3.0× · 3 peers
Peer P/S n/a 0% median 5.9× · 3 peers
Market Anchor (SMA50) $4.70 82% stability 89% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-11-19 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.3B
Employees
55
List Date
2020-10-30
CIK
0001593899
Last Earnings
Nov 9 before open · +2.3% vs ±30.2% expected
Headquarters
Boston, MA
Homepage
https://www.ateapharma.com

Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Month'21'22'23'24'25'26Avg
Jan76.24%-22.31%-3.74%29.60%-10.53%21.84%15.18%
Feb-0.30%-12.91%-23.38%2.13%3.77%14.99%-2.62%
Mar-16.29%11.76%3.08%-9.21%3.10%10.47%0.49%
Apr-57.26%-17.32%-4.66%-7.50%3.51%-2.48%-14.28%
May-11.14%28.34%22.39%-4.68%-0.67%-16.31%2.99%
Jun4.73%-3.79%-8.33%-14.91%16.13%6.16%-0.00%
Jul17.39%12.33%-5.77%13.35%1.11%-0.63%6.30%
Aug13.96%-9.53%-1.47%6.06%-3.17%16.05%3.65%
Sep22.46%-23.62%-10.45%-7.71%-14.71%-5.10%-6.52%
Oct-72.29%4.17%8.33%-2.70%12.85%-19.41%-11.51%
Nov-32.58%-22.61%-2.92%3.95%-4.62%-4.15%*-10.49%
Dec14.32%0.63%-2.24%-4.29%15.53%--4.79%
Total-79.53%-51.39%-30.49%-3.17%18.68%13.36%-22.09%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $4.18
SMA 50: $4.68
SMA 200: $4.95
Current: $3.92
EMA 12: $4.13
EMA 26: $4.30
MACD: -0.1674 | Signal: -0.0008
BEARISH
ADX (14): 27.70
TREND
+DI: 13.51
−DI: 25.56

Momentum Oscillators

RSI (14): 35.98
NEUTRAL
Stoch %K: 16.75
Stoch %D: 25.87
Williams %R: -88.37

Volume & Volatility

BB Upper: $4.46
BB Lower: $3.91
NEUTRAL
OBV: 19,550,545
Vol SMA 20: 295,471
Vol ROC: -31.22%
ATR: $0.24
True Range: $0.14
HV 20: 50.4%
HV 30: 54.5%
HV 60: 48.1%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-20T00:00:00 – 2026-11-18T00:00:00
AI Analysis
Written before AVIR’s Nov 9 earnings report, so it doesn’t reflect the results.

LLM Stock Analysis Report

Executive Summary

Overall Assessment: NEUTRAL (Confidence Level: 6/10)

Key Drivers:

  • Technical indicators suggest a range-bound market with no clear trend direction
  • Recent news headlines highlight the company's progress in developing new treatments, which could lead to increased investor interest
  • Risk metrics indicate low volatility, suggesting a relatively stable stock price

Primary Risks:

  • Lack of a clear trend direction or momentum signals
  • Potential impact from regulatory decisions or changes in market conditions

Investment Thesis:

AVIR's recent news highlights suggest the company is making progress in developing new treatments. This could lead to increased investor interest and potentially higher stock prices. However, without a clear trend direction, it's difficult to predict with certainty.

Recent News Sentiment Impact:

The positive sentiment from recent news headlines (60%) has contributed to the neutral overall assessment, as investors may be cautiously optimistic about AVIR's future prospects.

Technical Analysis

Trend Direction: Range-bound (1-4 weeks), Medium-term (1-3 months)

Support/Resistance Levels:

  • Lower band: $4.18
  • Middle line: $4.38
  • Upper band: $4.59

Momentum Signals:

  • RSI interpretation: Neutral (49.24)
  • MACD signal: Bearish (MACD: -0.09, Signal: 0.05)
  • Bollinger Bands position: Squeeze (Price touching middle line)

Volume Analysis:

  • Volume SMA 20: 276183.18
  • On-Balance Volume (OBV): 16626878.44
  • Volume Rate of Change: 4.00%

News & Sentiment Analysis

Recent Headlines Summary: Positive news headlines highlighting the company's progress in developing new treatments.

Sentiment Assessment: Positive sentiment dominates with 60% positive articles, indicating overall optimism about AVIR's future prospects.

Catalyst Identification: Upcoming earnings release and potential regulatory decisions may impact stock prices.

Market Narrative: Recent news highlights suggest the company is making progress, which could lead to increased investor interest. However, without a clear trend direction, it's difficult to predict with certainty.

Risk & Volatility Assessment

Beta Interpretation: Low risk relative to market (beta: 0.72)

Volatility Regime: Low volatility - stock moves less than market

Options Market Signals: IV rank: 65.5% (Medium), Options market pricing $2.60 move by expiration

Downside Protection: Support levels at $4.18 and $4.38, with a potential bounce if price touches these levels.

Market Context & Positioning

Sector Performance: Neutral sector performance, with no clear outperformance or underperformance relative to the broader market.

Institutional Activity: Moderate institutional interest with 12 calls vs 13 puts in options activity.

Correlation Analysis: Low correlation (0.18) suggests AVIR's stock price moves relatively independently of the broader market.

Relative Valuation: Position within a trading range, with no clear overbought or oversold signals.

Key Levels & Action Items

Critical Price Levels:

  • Support levels: $4.18 and $4.38
  • Resistance levels: $4.59 (upper band)

Breakout/Breakdown Levels:

  • Breakout above $4.59 for a potential uptrend
  • Breakdown below $4.18 for a potential downtrend

Time-Sensitive Catalysts: Upcoming earnings release and potential regulatory decisions.

Risk Management:

  • Stop-loss levels at $4.13 (lower band) and $4.43 (middle line)
  • Position sizing considerations based on risk tolerance and market conditions.
Generated
Earnings History
21 of 24 under expected move
Avg Expected Move
42.93%
Avg Actual Move
6.41%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-05-13 After-Close 17.69% 19.20% 1.09x Exceeded
2021-08-12 After-Close 14.01% 11.06% 0.79x Within
2021-11-12 After-Close 14.52% 1.23% 0.08x Within
2022-02-28 After-Close 26.03% 1.89% 0.07x Within
2022-05-10 After-Close 43.52% 2.73% 0.06x Within
2022-08-08 After-Close 16.18% 1.28% 0.08x Within
2022-11-07 After-Close 20.44% 9.88% 0.48x Within
2023-02-28 After-Close 35.59% 8.19% 0.23x Within
2023-05-08 After-Close 16.18% 2.65% 0.16x Within
2023-08-08 After-Close 37.54% 3.81% 0.10x Within
2023-11-08 After-Close 28.27% 9.12% 0.32x Within
2024-02-28 After-Close 18.99% 1.37% 0.07x Within
2024-05-14 After-Close 5.30% 6.31% 1.19x Exceeded
2024-08-07 After-Close 38.23% 7.03% 0.18x Within
2024-11-07 Pre-Market 205.31% 3.91% 0.02x Within
2025-01-14 After-Close 33.33% 5.40% 0.16x Within
2025-05-12 After-Close 20.27% 11.15% 0.55x Within
2025-08-07 Pre-Market 200.57% 0.86% 0.00x Within
2025-11-12 After-Close 58.57% 12.57% 0.21x Within
2026-01-08 Pre-Market 97.70% 3.74% 0.04x Within
2026-03-05 After-Close 16.51% 11.13% 0.67x Within
2026-05-12 After-Close 14.09% 16.91% 1.20x Exceeded
2026-08-12 Pre-Market 21.29% 0.20% 0.01x Within
2026-11-09 Pre-Market 30.16% 2.32% 0.08x Within

Earnings calendar: this week’s reports with expected vs actual moves →

AVIR Options Activity & IV Rank

AVIR IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 168.1%
7-DTE IV: —
Expected Move: $0.88
7-DTE Move: $1.05
Days to Exp: 29 (2026-12-18)

Options Flow · All expiries

Call Volume: 99
Put Volume: 44
P/C Volume: 0.444
BULLISH
Call OI: 516
Put OI: 534
P/C OI: 1.035
Total OI: 1,050

ATM Options Pricing

ATM Call: $0.10
ATM Put: $0.78
Call %: 2.5%
Put %: 19.7%

Chain Summary

Chain Volume: 143
Chain OI: 1,050
Last Updated: 11/19/2026

AVIR Implied Volatility

30-day IV
168.1%
Nov 19
IV rank
66Medium
Within its 90-session range

Loading implied volatility…

The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much AVIR actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.

Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
LOW γ vs HISTORY

Estimated net dealer gamma is at the 6th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
6%
vs own history
GEX tilt
+0.40
OI-weighted, today
Vanna tilt
+0.26
δ-sensitivity to IV
Charm tilt
-0.57
δ-decay vs time
Charm tilt -0.57: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 3 ATM contracts, 0k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
No data
30 DTE / 10d put —
— pts EXTREME
ATM 115.5% / Put —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)66.2MediumNov 19

Embed AVIR IV rank

AVIR's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$0.88Nov 19
Beta Analysis

Risk Metrics

Beta: 0.8820
Alpha: 27.57%
Correlation: 0.2404
R-Squared: 5.8%
Stock Volatility: 51.0%
Market Volatility: 13.9%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own AVIR
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Renaissance Technologies Hedge fund
Jim Simons
$5.7M
0.01%
#1376 of 3151-3.4%13F
Millennium Management Hedge fund
Izzy Englander
$1.4M
0.00%
#2760 of 3716-13.0%13F
Citadel Hedge fund
Ken Griffin
$731K
0.00%
#4054 of 6285+224.8%13F
Rockefeller Capital Management Family office
Rockefeller family
$12K
0.00%
#4113 of 48580.0%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

AVIR Institutional Ownership (13F)

Filings for 2026-09-30
Diluted shares outstanding: 79,374,086 (as of 2026-09-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

128 filers119,303,412 shares$592.36M value150.31% of float
# Filer Shares Value % of Total % of Float Period
1 FMR LLC Custodian 24,008,128 $111.64M 18.85% 30.25% 2026-06-30
2 BlackRock, Inc. Custodian 18,123,060 $94.42M 15.94% 22.83% 2026-09-30
3 BML Capital Management, LLC 13,507,316 $70.37M 11.88% 17.02% 2026-09-30
4 TANG CAPITAL MANAGEMENT LLC 9,629,400 $44.78M 7.56% 12.13% 2026-06-30
5 Vanguard Capital Management LLC 5,813,586 $30.29M 5.11% 7.32% 2026-09-30
6 ACADIAN ASSET MANAGEMENT LLC 4,676,542 $24.35M 4.11% 5.89% 2026-09-30
7 Geode Capital Management, LLC Custodian 3,820,578 $19.91M 3.36% 4.81% 2026-09-30
8 Bain Capital Life Sciences Investors, LLC 4,151,278 $19.30M 3.26% 5.23% 2026-06-30
9 State Street Corp 3,253,876 $16.95M 2.86% 4.10% 2026-09-30
10 Two Sigma Investments, LP Custodian 3,013,394 $14.01M 2.37% 3.80% 2026-06-30
11 Dimensional Fund Advisors LP Custodian 2,600,648 $13.55M 2.29% 3.28% 2026-09-30
12 RENAISSANCE TECHNOLOGIES LLC 2,185,800 $11.39M 1.92% 2.75% 2026-09-30
13 Rosalind Advisors, Inc. 2,141,100 $9.96M 1.68% 2.70% 2026-06-30
14 JPMorgan Chase & Co Custodian 1,850,568 $9.59M 1.62% 2.33% 2026-09-30
15 Northern Trust Corp Custodian 1,510,478 $7.02M 1.19% 1.90% 2026-06-30
16 Vanguard Portfolio Management LLC 1,279,936 $6.67M 1.13% 1.61% 2026-09-30
17 Morgan Stanley Custodian 1,112,938 $5.80M 0.98% 1.40% 2026-09-30
18 Charles Schwab Investment Management, Inc. 1,221,214 $5.68M 0.96% 1.54% 2026-06-30
19 Goldman Sachs Group Inc Custodian 1,061,712 $4.94M 0.83% 1.34% 2026-06-30
20 Vanguard Fiduciary Trust Co 939,446 $4.89M 0.83% 1.18% 2026-09-30
21 CM Management, LLC 900,000 $4.69M 0.79% 1.13% 2026-09-30
22 BANQUE PICTET & CIE SA 690,154 $3.60M 0.61% 0.87% 2026-09-30
23 Arrowstreet Capital, Limited Partnership 645,336 $3.36M 0.57% 0.81% 2026-09-30
24 D. E. Shaw & Co., Inc. Custodian 690,372 $3.21M 0.54% 0.87% 2026-06-30
25 Millennium Management LLC Custodian 609,222 $2.83M 0.48% 0.77% 2026-06-30
2 filers$135.42K notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $104.16K 76.92% 2026-06-30
2 Simplex Trading, LLC Custodian $31.26K 23.08% 2026-09-30
3 filers$401.17K notional
# Filer Notional Value % of Total Period
1 Jane Street Group, LLC Custodian $363.66K 90.65% 2026-09-30
2 Simplex Trading, LLC Custodian $19.28K 4.81% 2026-09-30
3 GROUP ONE TRADING LLC Custodian $18.23K 4.55% 2026-09-30

AVIR Insider Trading (Form 4)

Latest: 2026-11-18
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-11-18 Bruce Polsky Director Mixed
Sell −41,226 · Exer +75,000
+33,774 $2.25 -$75.1K EDGAR
2026-06-23 Bruno Lucidi Director Exer (M) +29,600 — EDGAR
2026-06-23 Jerome M. Adams Director Exer (M) +29,600 — EDGAR
2026-06-23 Howard Berman Director Grant (A) +64,400 RSU — EDGAR
2026-06-23 Bruce Polsky Director Exer (M) +29,600 — EDGAR
2026-06-23 Arthur S Kirsch Director Grant (A) +64,400 opt — EDGAR
2026-06-23 Polly A. Murphy Director Exer (M) +29,600 — EDGAR
2026-06-23 Franklin M Berger Director Exer (M) +29,600 — EDGAR
2026-06-23 Barbara Gayle Duncan Director Exer (M) +29,600 — EDGAR
2026-05-21 Polly A. Murphy Director Buy (P) +6,100 $4.17 $25.4K EDGAR
2026-05-20 Polly A. Murphy Director Buy (P) +6,100 $4.17 $25.4K EDGAR
2026-03-13 Andrea Corcoran See Remarks Exer (M) +60,000 $1.24 $74.4K EDGAR
2026-02-03 Andrea Corcoran See Remarks Mixed
Exer +54,866 · Tax −16,104
+38,762 $4.24 -$68.3K EDGAR
2026-02-03 Wayne Foster EVP, Chief Accounting Officer Mixed
Exer +41,333 · Tax −12,132
+29,201 $4.24 -$51.4K EDGAR
2026-02-03 Jean-Pierre Sommadossi President, CEO, and Chairman Mixed
Exer +572,983 · Tax −106,093
+466,890 $2.02 -$77.8K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

AVIR Insider Holdings

12 insiders · @ $3.92
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Jean-Pierre Sommadossi President, CEO, and Chairman 6,633,855 $26.04M -$457.0K 9 2026-02-03
2 Andrea Corcoran See Remarks 823,576 $3.23M -$60.9K 8 2026-03-13
3 Franklin M Berger Director 536,097 $2.10M -$238.2K 13 2026-06-23
4 Bruce Polsky Director 176,832 $694.1K -$229.2K 9 2026-11-18
5 John Vavricka Chief Commercial Officer 165,102 $648.0K -$45.4K 7 2026-02-03
6 Bruno Lucidi Director 142,350 $558.7K $0 8 2026-06-23
7 Polly A. Murphy Director 133,040 $522.2K $153.7K 11 2026-06-23
8 Janet MJ Hammond Chief Development Officer 127,665 $501.1K -$53.9K 6 2026-02-03
9 Maria Arantxa Horga Chief Medical Officer 96,086 $377.1K -$61.0K 6 2026-02-03
10 Barbara Gayle Duncan Director 92,350 $362.5K $0 8 2026-06-23
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

AVIR Board & Officers

As of SEC filings through Nov 18, 2026

Directors 9

Officers 6

Changes in the last 10 years (41)
Jun 20, 2025Howard Berman became a director
Feb 20, 2025Arthur S Kirsch became a director
Feb 2, 2022Wayne Foster listed as EVP, Chief Accounting Officer (previously SVP, Finance and Administration) in SEC filings
May 18, 2021Jerome M. Adams became a director
Feb 1, 2021Maria Arantxa Horga listed as Chief Medical Officer (previously Acting Chief Medical Officer) in SEC filings
Feb 1, 2021Andrea Corcoran listed as Chief Financial Officer, Executive Vice President, Legal and Secretary (previously CFO, General Counsel and Secretary) in SEC filings
Nov 5, 2020Cormorant Private Healthcare Fund II, LP reported in an SEC filing no longer being a 10% owner
Nov 5, 2020Cormorant Private Healthcare Fund I, LP reported in an SEC filing no longer being a 10% owner
Nov 5, 2020Cormorant Asset Management, LP reported in an SEC filing no longer being a 10% owner
Nov 5, 2020Bihua Chen reported in an SEC filing no longer being a director
Nov 5, 2020Bihua Chen reported in an SEC filing no longer being a 10% owner
Nov 4, 2020Rock Springs Capital Master Fund LP reported in an SEC filing no longer being a 10% owner
Nov 4, 2020Rock Springs Capital Management LP reported in an SEC filing no longer being a 10% owner
Nov 4, 2020Rock Springs Capital LLC reported in an SEC filing no longer being a 10% owner
Nov 3, 2020Jean-Pierre Sommadossi no longer listed as a 10% owner in SEC filings
Nov 3, 2020Chung K. Chu reported in an SEC filing no longer being a 10% owner
Oct 29, 2020Wayne Foster became SVP, Finance and Administration
Oct 29, 2020Rock Springs Capital Master Fund LP became a 10% owner
Oct 29, 2020Rock Springs Capital Management LP became a 10% owner
Oct 29, 2020Rock Springs Capital LLC became a 10% owner
Not reported recently (3)
  • Andrew A. F. Hack · Last reported as a director in an SEC filing dated Nov 3, 2020
  • Isaac Cheng · Last reported as a director in an SEC filing dated Oct 30, 2020
  • JPM Partners LLC · Last reported as a 10% owner in an SEC filing dated Oct 29, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

AVIR Proposed Insider Sales (Form 144)

Latest: 2026-11-18
Last 30d: 4 filings · $195K notice value  ·  Last 90d: 4 filings · $195K notice value · 2 unique filers

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: BRUCE POLSKY (3, $168K) · BRUNO LUCIDI (1, $27K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-11-18 BRUCE POLSKY Director 18,252 $72.1K 2026-11-18 Morgan Stanley Smith Barney LLC … — EDGAR
2026-11-17 BRUCE POLSKY Director 8,720 $35.2K 2026-11-17 Morgan Stanley Smith Barney LLC … — EDGAR
2026-11-17 BRUNO LUCIDI Director 6,741 $27.2K 2026-11-17 Morgan Stanley Smith Barney LLC … — EDGAR
2026-11-16 BRUCE POLSKY Director 14,254 $60.8K 2026-11-16 Morgan Stanley Smith Barney LLC … — EDGAR
2024-12-10 Franklin Berger Lead Independent Director 359,606 $1.02M 2024-12-10 J.P. Morgan Securities LLC — EDGAR
2024-09-19 JPM Partners LLC Affiliate 1,841 $7.4K 2024-09-19 UBS Financial Services Inc. 10b5-1 EDGAR
2024-09-18 JPM Partners LLC Affiliate 22,187 $89.5K 2024-09-18 UBS Financial Services Inc. 10b5-1 EDGAR
2024-09-17 JPM Partners LLC Affiliate 33,941 $137.3K 2024-09-17 UBS Financial Services Inc. 10b5-1 EDGAR
2024-06-20 Polsky Bruce Director 17,544 $68.8K 2024-06-20 MORGAN STANLEY SMITH BARNEY LLC … — EDGAR
2024-06-05 JPM Partners LLC Affiliate 1,006 $4.0K 2024-06-05 UBS Financial Services Inc. 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-09
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-09 Earnings results EDGAR
2026-11-09 Material agreement · New debt obligation EDGAR
2026-08-12 Earnings results EDGAR
2026-06-22 Shareholder vote results EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-09 0001193125-26-453807 EDGAR
2026-08-12 0001193125-26-347021 EDGAR
ETF Holders
36 ETFs hold AVIR
25 shown · $34.60M total exposure · 0.01% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.01% $7.3M $75.0B 2026-11-17
2 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $6.6M — 2026-10-31
3 VXF Vanguard Extended Market ETF Vanguard 0.00% $3.4M — 2026-10-31
4 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.02% $2.6M $13.6B 2026-11-17
5 DFAS Dimensional US Small Cap ETF Dimensional 0.01% $2.4M — 2026-11-17
6 IBB iShares Biotechnology ETF iShares (BlackRock) 0.02% $2.0M $10.9B 2026-11-17
7 SCHA Schwab U.S. Small-Cap ETF Nport 0.01% $1.8M — 2026-08-31
8 VTWO Vanguard Russell 2000 ETF Vanguard 0.01% $1.7M — 2026-10-31
9 DFMC Dimensional US Micro Cap ETF Dimensional 0.01% $964,898 — 2026-11-17
10 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.07% $858,413 $1.2B 2026-11-17
11 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $714,610 $93.0B 2026-11-17
12 VHT Vanguard Health Care ETF Vanguard 0.00% $645,397 — 2026-10-31
13 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.02% $596,380 $3.1B 2026-11-17
14 OMFS Invesco Russell 2000 Dynamic Multifactor ETF Invesco 0.20% $500,520 — 2026-11-17
15 FESM Fidelity Enhanced Small Cap Core ETF Fidelity 0.01% $373,630 $6.6B 2026-11-17
16 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.00% $354,816 — 2026-11-17
17 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $296,834 — 2026-11-17
18 ONEQ Fidelity Nasdaq Composite Index ETF Fidelity 0.00% $281,980 $10.1B 2026-11-17
19 VTWV Vanguard Russell 2000 Value ETF Vanguard 0.02% $269,316 — 2026-10-31
20 PRFZ Invesco RAFI US 1500 Small-Mid ETF Nport 0.01% $256,141 — 2026-07-31
21 SCHB Schwab U.S. Broad Market ETF Nport 0.00% $256,014 — 2026-08-31
22 RSSL Global X Russell 2000 ETF Global X 0.01% $132,596 — 2026-11-18
23 PKW Invesco BuyBack Achievers ETF Invesco 0.01% $127,619 — 2026-11-17
24 IWV iShares Russell 3000 ETF iShares (BlackRock) 0.00% $76,258 $19.9B 2026-11-17
25 DFAU Dimensional US Core Equity Market ETF Dimensional 0.00% $64,790 $12.5B 2026-11-17
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-1.96
TTM Revenue
$0.00
TTM Net Income
$-155.40M
TTM Op. Cash Flow
$-140.57M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q3 '262026-09-30$0.00$-32.16M$-0.40$-28.87M
Q2 '262026-06-30$0.00$-32.93M$-0.41$-37.08M
Q1 '262026-03-31$0.00$-45.44M$-0.57$-46.39M
Q4 '252025-12-31$0.00$-44.87M$-0.58$-28.22M
Q3 '252025-09-30$0.00$-42.05M$-0.53$-40.38M
Q2 '252025-06-30$0.00$-37.16M$-0.44$-32.87M
Q1 '252025-03-31—$-34.27M$-0.40$-30.56M
Q4 '242024-12-31—$-33.54M$-0.40$-30.40M
Q3 '242024-09-30—$-31.15M$-0.37$-23.04M
Q2 '242024-06-30—$-40.52M$-0.48$-42.20M
Q1 '242024-03-31—$-63.17M$-0.75$-39.87M
Q4 '232023-12-31—$-39.16M$-0.47$-21.83M
Q3 2026 • period ending 2026-09-30 • filed 2026-11-09
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.78
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-88.5%
ROA
-77.4%
Div Yield
0.00%
FCF Yield
-45.06%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$311.94M
as of 2026-11-19

AVIR vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
AMGN Amgen Inc $240.1B 25.5 +8.2% +34.3% 44
GILD Gilead Sciences Inc $209.6B — +6.5% +37.4% 64
VRTX Vertex Pharmaceuticals Inc $136.0B 33.6 +10.5% +15.5% 67
REGN Regeneron Pharmaceuticals Inc $97.8B 20.5 +18.6% +19.6% 68
MRNA Moderna, Inc. Common Stock $79.6B — +13.1% +549.8% 37
BIIB Biogen Inc. Common Stock $37.2B 105.9 +2.3% +39.3% 100
RVMD Revolution Medicines, Inc. Common Stock $34.6B — — +102.4% 75
UTHR United Therapeutics Corp $24.6B 21.2 +1.9% +13.1% 33
AVIR Atea Pharmaceuticals, Inc. Common Stock $320M — — +12.8% 66
Peer median $88.7B 25.5 +8.2% +35.8% 65

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
3.01M
SI % of Float
4.92%
Days to Cover
9.55
Short Vol Ratio
60.9%
Free Float
61.12M
Float %
76.2%
Short interest 2026-10-30 • Short volume 2026-11-18 • Float 2026-09-22